

IN THE SPECIFICATION

Please amend the paragraph beginning at page 13, line 5, as follows:

In another embodiment, the invention provides a use of a peptide or a protein selected from Apolipoprotein B; a fragment thereof or a mimetic thereof; Apolipoprotein E (SEQ ID NO: 2); a fragment thereof and a mimetic thereof, preferably Apolipoprotein B or a fragment thereof, in a screening assay for the identifying compounds that modulate the conversion of PrP<sup>c</sup> into PrP<sup>Sc</sup>.

Please amend the paragraph beginning at page 15, line 1, as follows:

In another preferred embodiment of the invention, the modulator is an antibody raised against a fragment of Apolipoprotein B (SEQ ID NO: 1), which fragment comprises a sequence selected from fragments taken between positions 3201-3558, 3548-3905, 3201-3905, 3291-3558, 3548-3815, and 3291-3815.

Please amend the paragraph beginning at page 28, line 16, as follows:

PrP cDNA was amplified by RT-PCR from both cell lines as follows:  
Total RNA of N2a cells is prepared using Trizol (Gibco) and the mouse PrP cDNA is reversed transcribed with Omniscript (Qiagen) using the protocol supplied by the manufacturer. The specific primer for cDNA synthesis is 5' TCAATTGAAAGAGCTACAGGTG 3' (SEQ ID NO: 4). The prion cDNA is amplified using standard PCR conditions in the presence of primers 5' ACCAGTCCAATTTAGGAGAGCC 3' (SEQ ID NO: 5) (top strand) and 5' AGACCACGAGAATGCGAAGG 3' (SEQ ID NO: 6) (bottom strand). The PCR product was completely sequenced in the automated ABI3700 using the reagents and the protocol supplied by the manufacturer.

Please delete the original Sequence Listing.

Page 39 (Abstract), after the last line, beginning on a new page, please insert the attached substitute Sequence Listing.